GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » DMK Pharmaceuticals Corp (FRA:CY3) » Definitions » Cyclically Adjusted PB Ratio

DMK Pharmaceuticals (FRA:CY3) Cyclically Adjusted PB Ratio : 0.01 (As of Jun. 10, 2024)


View and export this data going back to . Start your Free Trial

What is DMK Pharmaceuticals Cyclically Adjusted PB Ratio?

As of today (2024-06-10), DMK Pharmaceuticals's current share price is €3.444. DMK Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Sep. 2023 was €290.82. DMK Pharmaceuticals's Cyclically Adjusted PB Ratio for today is 0.01.

The historical rank and industry rank for DMK Pharmaceuticals's Cyclically Adjusted PB Ratio or its related term are showing as below:

During the past years, DMK Pharmaceuticals's highest Cyclically Adjusted PB Ratio was 71.11. The lowest was 0.01. And the median was 1.90.

FRA:CY3's Cyclically Adjusted PB Ratio is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.89
* Ranked among companies with meaningful Cyclically Adjusted PB Ratio only.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

DMK Pharmaceuticals's adjusted book value per share data for the three months ended in Sep. 2023 was €-0.491. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €290.82 for the trailing ten years ended in Sep. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


DMK Pharmaceuticals Cyclically Adjusted PB Ratio Historical Data

The historical data trend for DMK Pharmaceuticals's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DMK Pharmaceuticals Cyclically Adjusted PB Ratio Chart

DMK Pharmaceuticals Annual Data
Trend Mar13 Mar14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 16.64 2.17 0.98 1.01 0.23

DMK Pharmaceuticals Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.28 0.23 0.15 0.04 0.01

Competitive Comparison of DMK Pharmaceuticals's Cyclically Adjusted PB Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, DMK Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


DMK Pharmaceuticals's Cyclically Adjusted PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, DMK Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where DMK Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.



DMK Pharmaceuticals Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

DMK Pharmaceuticals's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=3.444/290.82
=0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

DMK Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Sep. 2023 is calculated as:

For example, DMK Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Sep. 2023 was:

Adj_Book=Book Value per Share/CPI of Sep. 2023 (Change)*Current CPI (Sep. 2023)
=-0.491/129.8595*129.8595
=-0.491

Current CPI (Sep. 2023) = 129.8595.

DMK Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201312 52.062 98.326 68.759
201403 58.739 99.695 76.512
201406 47.374 100.560 61.177
201409 65.809 100.428 85.095
201412 0.000 99.070 0.000
201503 85.477 99.621 111.422
201506 68.969 100.684 88.954
201509 57.333 100.392 74.162
201512 44.559 99.792 57.984
201603 40.610 100.470 52.489
201606 54.087 101.688 69.071
201609 73.930 101.861 94.251
201612 76.283 101.863 97.249
201703 60.377 102.862 76.224
201706 76.117 103.349 95.642
201709 80.973 104.136 100.975
201712 70.058 104.011 87.469
201803 56.869 105.290 70.140
201806 45.581 106.317 55.674
201809 73.355 106.507 89.439
201812 60.750 105.998 74.426
201903 51.942 107.251 62.892
201906 43.967 108.070 52.832
201909 41.558 108.329 49.818
201912 33.626 108.420 40.275
202003 28.538 108.902 34.030
202006 19.442 108.767 23.212
202009 17.383 109.815 20.556
202012 2.145 109.897 2.535
202103 21.798 111.754 25.329
202106 18.216 114.631 20.636
202109 13.776 115.734 15.457
202112 10.718 117.630 11.832
202203 6.749 121.301 7.225
202206 3.109 125.017 3.229
202209 1.341 125.227 1.391
202212 -0.356 125.222 -0.369
202303 -3.802 127.348 -3.877
202306 -3.911 128.729 -3.945
202309 -0.491 129.860 -0.491

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


DMK Pharmaceuticals  (FRA:CY3) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


DMK Pharmaceuticals Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of DMK Pharmaceuticals's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


DMK Pharmaceuticals (FRA:CY3) Business Description

Traded in Other Exchanges
Address
11682 El Camino Real, Suite 300, San Diego, CA, USA, 92130
DMK Pharmaceuticals Corp Formerly Adamis Pharmaceuticals Corp is a specialty biopharmaceutical company focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease. Its products and product candidates in the allergy, respiratory, and opioid overdose markets include SYMJEPI (epinephrine) Injection 0.3mg and Injection 0.15mg for use in the emergency treatment of acute allergic reactions, including anaphylaxis; a naloxone injection product candidate, ZIMHI, based on the approved Symject injection device and intended for the treatment of opioid overdose; Tempol, an investigational drug; and a Beclomethasone metered dose inhaler product candidate (APC-400) intended for the treatment of Covid-19.

DMK Pharmaceuticals (FRA:CY3) Headlines

No Headlines